Evidence map›Paper›PMID 37095202›Full record

ReviewAbdominal radiology (New York)2023

Noninvasive prenatal screening and maternal malignancy: role of imaging.

Priyanka Jha, Liesbeth Lenaerts, Joris Vermeesch, Mary Norton, Frédéric Amant, Phyllis Glanc, Liina Poder

Open access · greenAbstract readReview
PubMed Publisher
In one paragraph

Review in Abdominal radiology (New York), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Noninvasive prenatal testing: an overview.Australian prescriber · 2025
    Review
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 4 countries.

Priyanka JhaDepartment of Radiology, Division of Body Imaging, Stanford University School of Medicine, Palo Alto, CA, USA. jhap@stanford.edu.ORCID http://orcid.org/0000-0001-5417-7723
Liesbeth LenaertsDepartment of Oncology, KU Leuven, Leuven, Belgium.
Joris VermeeschDepartment of Human Genetics, KU Leuven, Leuven, Belgium.
Mary NortonDepartment of Obstetrics and Gynecology, University of California San Francisco, San Francisco, CA, USA.
Frédéric AmantDepartment of Oncology, KU Leuven, Leuven, Belgium.
Phyllis GlancDepartment of Radiology, Obstetrics & Gynecology, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Liina PoderDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
KU Leuven · BEUniversity of California, San Francisco · USStanford Medicine · USSunnybrook Health Science Centre · CAThe Netherlands Cancer Institute · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Noninvasive prenatal screening (NIPS) tests for fetal chromosomal anomalies through maternal blood sampling. It is becoming widely available and standard of care for pregnant women in many countries. It is performed in the first trimester of pregnancy, usually between 9 and 12 weeks. Fragments of fetal cell-free deoxyribonucleic acid (DNA) floating in maternal plasma are detected and analyzed by this test to assess for chromosomal aberrations. Similarly, maternal tumor-derived cell-free DNA (ctDNA) released from the tumor cells also circulates in the plasma. Hence, the presence of genomic anomalies originating from maternal tumor-derived DNA may be detected on the NIPS-based fetal risk assessment in pregnant patients. Presence of multiple aneuploidies or autosomal monosomies are the most commonly reported NIPS abnormalities detected with occult maternal malignancies. When such results are received, the search for an occult maternal malignancy begins, in which imaging plays a crucial role. The most commonly detected malignancies via NIPS are leukemia, lymphoma, breast and colon cancers. Ultrasound is a reasonable radiation-free modality for imaging during pregnancy, specially when there are localizing symptoms or findings, such as palpable lumps. While there are no consensus guidelines on the imaging evaluation for these patients, when there are no localizing symptoms or clinically palpable findings, whole body MRI is recommended as the radiation-free modality of choice to search for an occult malignancy. Based on clinical symptoms, practice patterns, and available resources, breast ultrasound, chest radiographs, and targeted ultrasound evaluations can also be performed initially or as a follow-up for MRI findings. CT is reserved for exceptional circumstances due to its higher radiation dose. This article intends to increase awareness of this rare but stressful clinical scenario and guide imaging evaluation for occult malignancy detected via NIPS during pregnancy.

Indexed as

NeoplasmsNoninvasive Prenatal TestingAneuploidyDNAFemaleHumansPregnancyPrenatal DiagnosisDNACancer in pregnancyImaging in pregnancyNIPSNIPTNoninvasive prenatal testingPostpartum cancer

Identifiers

PMID37095202
OpenAlexW4366815233

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.